Allylic alcohols of unexpected configuration by oxazaborolidine-catalysed reduction of α,β-unsaturated ketones. An explanation based on MO calculations
摘要:
While the reduction of most alpha,beta-unsaturated ketones with BH3:SMe(2) in the presence of (R)B-methyl-4,5,5-triphenyl-1,3,2-oxazaborolidine [(R)-2] affords allylic alcohols of the S configuration, that of alpha,beta-unsaturated ketones branched at both the alpha and alpha' positions gives alcohols of the R configuration. Theoretical calculations on complexes of representative enones with BH3 (6-31G*) or with BH3:(R)-2 (AMI) may account for the apparent changes in the steric requirements on either side of the CO group.
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
申请人:AMGEN INC.
公开号:US20180177767A1
公开(公告)日:2018-06-28
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS
申请人:TACHDJIAN Catherine
公开号:US20130295261A1
公开(公告)日:2013-11-07
The present invention provides isosorbide derivatives having the formula shown below and certain subgenera or species thereof, as flavor or taste modifiers, particularly, savory (“umami”) taste modifiers, savory flavoring agents and savory flavor enhancers in foods, beverages, and other comestible compositions,
Catalyst for asymmetric epoxidation of enones and process for producing optically active epoxide employing it
申请人:——
公开号:US20010051737A1
公开(公告)日:2001-12-13
A complex catalyst for asymmetric epoxidation of enones, which comprises:
(A) an optically active binaphthol,
(B) lanthanum triisopropoxide,
(C) triphenylphosphine oxide, and
(D) cumene hydroperoxide or tert-butyl hydroperoxide.
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
申请人:Capella Therapeutics, Inc.
公开号:US10005765B2
公开(公告)日:2018-06-26
Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.